Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Madrigal pens $4.4B deal for Ribo’s preclinical siRNA programs in latest Rezdiffra MASH play

Madrigal pens $4.4B deal for Ribo’s preclinical siRNA programs in latest Rezdiffra MASH play

  • February 11, 2026

Madrigal Pharmaceuticals is continuing to splash the cash this year on liver disease drugs it can combine with its own potential blockbuster Rezdiffra.

Leave A Comment

Fields (*) Mark are Required